SpyGlass Pharma, Inc. (SGP) Financials

SpyGlass Pharma, Inc. (SGP) recorded an outflow of $33.5M in free cash flow during fiscal year 2025. This represents a -39.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

SpyGlass Pharma, Inc. (SGP) recorded an outflow of $32.7M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

SpyGlass Pharma, Inc. (SGP) had $115.9M in total assets as of fiscal year 2025, including both current and long-term assets.

SpyGlass Pharma, Inc. (SGP) invested $789K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

SpyGlass Pharma, Inc. (SGP) invested $29.2M in research and development during fiscal year 2025.

Yes, SpyGlass Pharma, Inc. (SGP) spent $1.4M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

SpyGlass Pharma, Inc. (SGP) had 33M shares outstanding as of fiscal year 2025.

SpyGlass Pharma, Inc. (SGP) had a current ratio of 12.67 as of fiscal year 2025, which is generally considered healthy.

SpyGlass Pharma, Inc. (SGP) had a return on assets of -34.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

SpyGlass Pharma, Inc. (SGP) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $945.9M as of Sep 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

SpyGlass Pharma, Inc. (SGP) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $945.9M as of Sep 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

At the end of fiscal year 2025, SpyGlass Pharma, Inc. (SGP) held $96.4M in cash, cash equivalents and investments, and reported an operating cash outflow of $32.7M over that year. Dividing the one by the other, the reported balance equals about 35 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

SpyGlass Pharma, Inc. (SGP) has negative shareholder equity of -$98.8M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

SpyGlass Pharma, Inc. (SGP) has a Piotroski F-Score of 3 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

SpyGlass Pharma, Inc. (SGP) reported a net loss of $39.9M while operations used $32.7M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.